MedPath

Phase II trial of nab-paclitaxel and carboplatin with concurrent radiotherapy for patients with locally advanced non-small cell lung cancer

Not Applicable
Conditions
non-small cell lung cancer
Registration Number
JPRN-UMIN000019611
Lead Sponsor
Department of Radiation Oncology, Yamaguchi University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
37
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patient with a history of allergy to taxane antineoplastic agents 2. Patient with a history of allergy to carboplatin or other platinum-based antineoplastic agents 3. Patient with a history of allergy to albumin 4. without the concent to the risk of infection caused by albumin preparation 5. Patients with active infection 6. Patients with serious complications (e.g. heart failure, severe pulmonary emphysema, renal disfunction, hepatic disfunction, poorly controlled diabetes or hypertension) 7. Patient with severe bone marrow suppression 8. Patient with active double cancer within 5years prior to the study 9. Patients with pleural or pericardial effusion, or ascites. 10. Patient with motor paralysis or neuropathy, except due to NSCLC 11. Exhibiting significant interstitial pneumonitis, or pulmonary fibrosis in the chest radiograph 12. Patient with collagen vascular diseases 13. Female Patient in or having a chance or planning of pregnancy or breast feeding 14. Male patient in planning to impregnate 15. Inappropriate patients for this study judged by the attending physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Responce Rate
Secondary Outcome Measures
NameTimeMethod
Completion rate of the protocol treatment, Progression Free Survival, Overall Survival, Safety, Relative Dose Intensity
© Copyright 2025. All Rights Reserved by MedPath